Patent application number | Description | Published |
20100052366 | Tube Arrangement and Crossbeam Having Such a Tube Arrangement - A tube arrangement comprises a first tube and at least one second tube, the first tube and the second tube being arranged in relation to one another with an offset transversely with respect to the longitudinal direction of the tubes and with a partial overlap region in the longitudinal direction of the tubes, so that a first end of the first tube is arranged at a side of the second tube and a second end of the second tube is arranged at a side of the first tube. The tube arrangement has, further, at least one connection element which fixedly connects the first tube and the second tube to one another in the overlap region. The connection element has a first end wall and a second end wall spaced apart from the first end wall in the longitudinal direction of the tubes, which end walls extend, in the overlap region, between the tubes transversely with respect to the longitudinal direction of the latter and are fixedly connected to these, and two longitudinal walls which are spaced apart from one another transversely with respect to the longitudinal direction and which extend in the longitudinal direction of the tubes from the first end wall to the second end wall and are fixedly connected to these. | 03-04-2010 |
20140049075 | CONNECTION ARRANGEMENT AND CROSSMEMBER - A connection arrangement for connecting two tube pieces of a crossmember for a vehicle has a first attachment element made of a first material, wherein the first attachment element is provided for a solid material-bonded connection to at least a first tube piece which comprises the first material. Furthermore, the first attachment element has a second attachment element which is fastened to the first attachment element, wherein the second attachment element consists essentially of a second material differing from the first material, wherein the second attachment element is provided for a solid material-bonded connection to a second tube piece which comprises the second material. Furthermore, a crossmember has such a connection arrangement. | 02-20-2014 |
Patent application number | Description | Published |
20080207580 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 08-28-2008 |
20080227761 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 09-18-2008 |
20090010885 | Methods for Detecting and Treating Autoimmune Disorders - The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease. | 01-08-2009 |
20090280135 | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, to treat or prevent autoimmune or neurodegenerative diseases, to protect axons, and to prevent or reverse demyelination. | 11-12-2009 |
20110124614 | Methods And Compositions For The Treatment of Autoimmune Disorders - Methods and compositions are provided which confer protection against autoimmune diseases without triggering intracellular estrogen receptors. Such methods and compositions limit the side effects of steroids while providing the benefits conferred by such medications through the activation of membrane estrogen receptors. | 05-26-2011 |
20110217308 | Compositions and methods using recombinant MHC molecules for the treatment of stroke - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 09-08-2011 |
20140056936 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 02-27-2014 |
Patent application number | Description | Published |
20110059093 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 03-10-2011 |
20120213774 | Antibodies against human IL33R and uses thereof - An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases. | 08-23-2012 |
20130084637 | SINGLE B-CELL CULTIVATION METHOD - Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG | 04-04-2013 |
20130310541 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 11-21-2013 |
20140302015 | ANTIBODIES AGAINST HUMAN IL33R AND USES THEREOF - An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases. | 10-09-2014 |
20140315252 | CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE - Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21. | 10-23-2014 |